COST-EFFECTIVENESS OF PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC ESOPHAGEAL CANCER OR HER2-NEGATIVE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA IN FRANCE

被引：0
|
作者：
Aparicio, T. [1 ]
Mackosso, C. [2 ]
Cagnan, L. [3 ]
Bensimon, L. [3 ]
Tehard, B. [4 ]
Boussahoua, M. [4 ]
Zhang, S. [5 ]
Qu, T. [6 ]
Meng, Y. [7 ]
Francois, E. [8 ]
机构：
[1] St Louis Hosp, Paris, NJ, France
[2] MSD France, Puteaux La Defense, France
[3] MSD France, Paris, France
[4] Vyoo Agcy, Paris 75, France
[5] Merck, Rahway, NJ USA
[6] Luminaty, Bethesda, MD USA
[7] Luminaty, Las Vegas, NV USA
[8] Ctr Antoine Lacassagne, Nice, France
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE284
引用
收藏
页码：S109 / S109
页数：1
相关论文
共 50 条
  • [1] Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer
    Hirose, Toshiharu
    Yamamoto, Shun
    Kato, Ken
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
  • [2] Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
    Zhu, Youwen
    Liu, Kun
    Ding, Dong
    Zhou, Yangying
    Peng, Libo
    [J]. ADVANCES IN THERAPY, 2022, 39 (06) : 2614 - 2629
  • [3] Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
    Youwen Zhu
    Kun Liu
    Dong Ding
    Yangying Zhou
    Libo Peng
    [J]. Advances in Therapy, 2022, 39 : 2614 - 2629
  • [4] Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan
    Morimoto, Kosuke
    Moriwaki, Kensuke
    Shimozuma, Kojiro
    Nakayama, Takeo
    [J]. JOURNAL OF GASTROENTEROLOGY, 2023, 58 (12) : 1188 - 1197
  • [5] Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan
    Kosuke Morimoto
    Kensuke Moriwaki
    Kojiro Shimozuma
    Takeo Nakayama
    [J]. Journal of Gastroenterology, 2023, 58 : 1188 - 1197
  • [6] Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma
    Jiang, Yuan
    Li, Yue
    Wang, Larry X. W.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (02) : 499 - 506
  • [7] Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma
    Yuan Jiang
    Yue Li
    Larry X. W. Wang
    [J]. International Journal of Clinical Pharmacy, 2022, 44 : 499 - 506
  • [8] Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first-line treatment for advanced esophageal cancer
    Ye, Zhuo-Miao
    Xu, Zhe
    Wang, Hao-Lun
    Wang, Ying-Yuan
    Chen, Ze-Chang
    Zhou, Qin
    Li, Xiang-Ping
    Zhang, Ying-Ying
    [J]. CANCER MEDICINE, 2023, 12 (05): : 6182 - 6189
  • [9] Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis
    Peng-Fei Zhang
    Xuan-Qiong Shi
    Qiu Li
    [J]. Cost Effectiveness and Resource Allocation, 21
  • [10] Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis
    Zhang, Peng-Fei
    Shi, Xuan-Qiong
    Li, Qiu
    [J]. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
12345